CAS: 1246303-14-9

VU0359595 (ML-270) is a selective PLD1 inhibitor with 3.7 nM IC50; >1700x more selective over PLD2, for cancer/diabetes/neurodegenerative research.

VU0359595

VU0359595 is a selective negative allosteric modulator that targets the metabotropic glutamate receptor 5 (mGluR5), which is primarily sourced from synthetic chemical libraries. This compound acts by binding to a site distinct from the active site on mGluR5, effectively inhibiting the receptor's activity without directly competing with endogenous ligands. By altering the receptor's conformation, VU0359595 modulates downstream signaling pathways, which can be pivotal in understanding synaptic transmission and plasticity. In terms of applications, VU0359595 has become valuable in the field of neuroscience research, particularly in the study of various neurological and psychiatric disorders. Its ability to modulate mGluR5 provides insights into potential therapeutic interventions for conditions such as anxiety, depression, schizophrenia, and neurodegenerative diseases. Researchers leverage this compound to dissect the receptor's role in pathophysiology, potentially contributing to the development of more targeted and effective therapeutic strategies. The specificity of VU0359595 makes it an essential tool for elucidating the complex mechanisms underpinning mGluR5's involvement in central nervous system functions.